WEBULL

Tyra Biosciences (TYRA): Assessing Valuation After New Leadership Hires to Drive Dabogratinib Pipeline Forward

Simply Wall St · 2d ago

Tyra Biosciences (TYRA) is shaking up its leadership team, bringing in seasoned operators Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer, with a clear focus on advancing oral dabogratinib.

See our latest analysis for Tyra Biosciences.

The leadership shake up lands at a time when sentiment is already improving, with a roughly 45 percent 1 month share price return helping drive a stronger 3 month share price performance and underlining building momentum on top of an impressive 3 year total shareholder return.

If you are watching Tyra for execution on its pipeline, it could also be a good moment to scout other innovative biotech names through healthcare stocks.

Yet with shares up over 70 percent in three months but still trading at a steep discount to analyst targets, is Tyra a high conviction entry point on execution upside, or are markets already pricing in the next leg of growth?

Price to Book of 4.1x: Is it justified?

On a price to book basis, Tyra trades richer than the typical US biotech peer, hinting that recent share price strength already embeds optimism.

The price to book ratio compares a company’s market value to its net assets and is a common yardstick for pre revenue, loss making biotechs where earnings based metrics are not yet meaningful.

For Tyra, a 4.1x multiple stands well above the broader US biotech industry average of 2.5x, suggesting investors are willing to pay a premium for its FGFR focused pipeline and management track record, even though the company remains unprofitable and is forecast to stay that way over the next three years.

At the same time, that 4.1x multiple looks far more restrained when set against a much higher 28.3x average for closer peers, underscoring how Tyra can screen expensive versus the wider industry but still appear comparatively modest in a cohort of high expectation, early stage drug developers.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price to Book of 4.1x (ABOUT RIGHT)

However, Tyra remains a pre revenue, loss making biotech, and any clinical setback or delay in dabogratinib or TYRA 300 could quickly cool current optimism.

Find out about the key risks to this Tyra Biosciences narrative.

Build Your Own Tyra Biosciences Narrative

If you see the story differently and want to dig into the numbers yourself, you can build a personalized view in just minutes, Do it your way.

A great starting point for your Tyra Biosciences research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Before momentum shifts again, put Simply Wall St to work for you by hunting fresh opportunities across themes and sectors that could complement your view on Tyra.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.